315 related articles for article (PubMed ID: 22487725)
1. Is the measurement of anti-Müllerian hormone essential?
Usta T; Oral E
Curr Opin Obstet Gynecol; 2012 Jun; 24(3):151-7. PubMed ID: 22487725
[TBL] [Abstract][Full Text] [Related]
2. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
[TBL] [Abstract][Full Text] [Related]
3. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
La Marca A; Sighinolfi G; Radi D; Argento C; Baraldi E; Artenisio AC; Stabile G; Volpe A
Hum Reprod Update; 2010; 16(2):113-30. PubMed ID: 19793843
[TBL] [Abstract][Full Text] [Related]
4. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
[TBL] [Abstract][Full Text] [Related]
5. Relevance of anti-Mullerian hormone measurement in a routine IVF program.
Gnoth C; Schuring AN; Friol K; Tigges J; Mallmann P; Godehardt E
Hum Reprod; 2008 Jun; 23(6):1359-65. PubMed ID: 18387961
[TBL] [Abstract][Full Text] [Related]
6. [Clinical applications of anti-Müllerian hormone in evaluating ovarian reserve functions].
Yu M; Deng CY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):114-9. PubMed ID: 19317075
[TBL] [Abstract][Full Text] [Related]
7. [Measurement of serum AMH levels in gynecology: indications and limits].
Streuli I; Cantero-Perez P; Miserez-Zaugg C
Rev Med Suisse; 2013 Oct; 9(403):1954-6, 1958. PubMed ID: 24245018
[TBL] [Abstract][Full Text] [Related]
8. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients.
Aleyasin A; Aghahoseini M; Mokhtar S; Fallahi P
Acta Med Iran; 2011; 49(11):715-20. PubMed ID: 22131240
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-Müllerian hormone in female fertility and infertility - an overview.
Grynnerup AG; Lindhard A; Sørensen S
Acta Obstet Gynecol Scand; 2012 Nov; 91(11):1252-60. PubMed ID: 22646322
[TBL] [Abstract][Full Text] [Related]
10. [Anti mullerian hormone (AMH)--is it a new reliable marker of the ovarian reserve? Its role in predicting the ovarian response in assisted reproductive technology (ART)].
Alshiek JA; Lessing JB; Amit A; Azem F
Harefuah; 2012 Jul; 151(7):416-20, 435. PubMed ID: 23002694
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan.
Tremellen K; Zander-Fox D
Aust N Z J Obstet Gynaecol; 2015 Aug; 55(4):384-9. PubMed ID: 26230428
[TBL] [Abstract][Full Text] [Related]
12. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles.
Tolikas A; Tsakos E; Gerou S; Prapas Y; Loufopoulos A
Hum Fertil (Camb); 2011 Dec; 14(4):246-53. PubMed ID: 22088130
[TBL] [Abstract][Full Text] [Related]
13. Anti-mullerian hormone as a marker of ovarian reserve.
Tremellen KP; Kolo M; Gilmore A; Lekamge DN
Aust N Z J Obstet Gynaecol; 2005 Feb; 45(1):20-4. PubMed ID: 15730360
[TBL] [Abstract][Full Text] [Related]
14. Anti-Müllerian hormone and polycystic ovary syndrome: assessment of the clinical pregnancy rates in in vitro fertilization patients.
Sahmay S; Guralp O; Aydogan B; Cepni I; Oral E; Irez T
Gynecol Endocrinol; 2013 May; 29(5):440-3. PubMed ID: 23461296
[TBL] [Abstract][Full Text] [Related]
15. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.
Yates AP; Rustamov O; Roberts SA; Lim HY; Pemberton PW; Smith A; Nardo LG
Hum Reprod; 2011 Sep; 26(9):2353-62. PubMed ID: 21672928
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
18. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in the utility of anti-Müllerian hormone in female infertility.
Grynnerup AG; Lindhard A; Sørensen S
Curr Opin Obstet Gynecol; 2014 Jun; 26(3):162-7. PubMed ID: 24722366
[TBL] [Abstract][Full Text] [Related]
20. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
Tal R; Seifer DB; Khanimov M; Malter HE; Grazi RV; Leader B
Am J Obstet Gynecol; 2014 Jul; 211(1):59.e1-8. PubMed ID: 24593938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
